Rigel Pharmaceuticals (RIGL) Liabilities and Shareholders Equity (2010 - 2026)

Rigel Pharmaceuticals' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $504.6 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 186.75% year-over-year to $504.6 million; the TTM figure through Mar 2026 stood at $1.5 billion (up 141.45% YoY), while the FY2025 annual figure was $513.6 million, up 213.21% from the prior year.
• Liabilities and Shareholders Equity was $504.6 million for Q1 2026 at Rigel Pharmaceuticals, down from $513.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $513.6 million in Q4 2025 to a low of $115.3 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $188.4 million across 5 years, with a median of $134.3 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity sank 38.02% in 2022, then soared 213.21% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $134.3 million in 2022, then decreased by 12.7% to $117.2 million in 2023, then soared by 39.88% to $164.0 million in 2024, then jumped by 213.21% to $513.6 million in 2025, then decreased by 1.75% to $504.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $504.6 million (Q1 2026), $513.6 million (Q4 2025), and $242.5 million (Q3 2025), per Business Quant data.